Trial · NCT03107793
Results by group171
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 171
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 48 | Maintenance Period: Treat to Target | 37.9 | 95% Confidence Interval 31.4 | Percentage of Participants | |
| Percentage of Participants With Endoscopic Response at Week 48 | Maintenance Period: Routine Care | 29.9 | 95% Confidence Interval 23.9 | Percentage of Participants | |
| Percentage of Participants With Endoscopic Response at Week 48 (Premature Drop-outs Excluded) | Maintenance Period: Treat to Target | 43.0 | 95% Confidence Interval 35.9 | Percentage of Participants | |
| Percentage of Participants With Endoscopic Response at Week 48 (Premature Drop-outs Excluded) | Maintenance Period: Routine Care | 32.3 | 95% Confidence Interval 25.9 | Percentage of Participants | |
| Percentage of Participants With Endoscopic Response at Week 48 (Last Observation Carried Forward [LOCF]) | Maintenance Period: Treat to Target | 40.2 | 95% Confidence Interval 33.6 | Percentage of Participants | |
| Percentage of Participants With Endoscopic Response at Week 48 (Last Observation Carried Forward [LOCF]) | Maintenance Period: Routine Care | 30.8 | 95% Confidence Interval 24.8 | Percentage of Participants | |
| Percentage of Participants With Clinical Response at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Week 16 | 84.5 | 95% Confidence Interval 80.0 to 89.8 | Percentage of Participants |
| Percentage of Participants With Clinical Response at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Routine Care | Week 16 | 89.6 | 95% Confidence Interval 84.8 to 93.3 | Percentage of Participants |
| Percentage of Participants With Clinical Response at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Week 48 | 68.0 | 95% Confidence Interval 61.4 to 74.2 | Percentage of Participants |
| Percentage of Participants With Clinical Response at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Routine Care | Week 48 | 77.8 | 95% Confidence Interval 71.8 to 83.1 | Percentage of Participants |
| Percentage of Participants With Clinical Response at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Endpoint (Week 48 [LOCF]) | 89.5 | 95% Confidence Interval 84.7 to 93.2 | Percentage of Participants |
| Percentage of Participants With Clinical Response at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Routine Care | Endpoint (Week 48 [LOCF]) | 89.6 | 95% Confidence Interval 84.8 to 93.3 | Percentage of Participants |
| Percentage of Participants With Clinical Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Week 16 | 72.1 | 95% Confidence Interval 65.7 to 78.0 | Percentage of Participants |
| Percentage of Participants With Clinical Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Routine Care | Week 16 | 74.2 | 95% Confidence Interval 67.9 to 79.8 | Percentage of Participants |
| Percentage of Participants With Clinical Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Week 48 | 61.6 | 95% Confidence Interval 54.9 to 68.1 | Percentage of Participants |
| Percentage of Participants With Clinical Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Routine Care | Week 48 | 69.7 | 95% Confidence Interval 63.2 to 75.7 | Percentage of Participants |
| Percentage of Participants With Clinical Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Endpoint (Week 48 [LOCF]) | 77.2 | 95% Confidence Interval 71.0 to 82.6 | Percentage of Participants |
| Percentage of Participants With Clinical Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Routine Care | Endpoint (Week 48 [LOCF]) | 78.3 | 95% Confidence Interval 72.3 to 83.5 | Percentage of Participants |
| Percentage of Participants With Endoscopic Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Week 16 | 11.4 | 95% Confidence Interval 7.5 to 16.4 | Percentage of Participants |
| Percentage of Participants With Endoscopic Remission at Weeks 16, 48, and Endpoint (Week 48 [LOCF]) | Maintenance Period: Treat to Target | Week 48 | 11.4 | 95% Confidence Interval 7.5 to 16.4 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03107793/results